Treatment of Human Embryonic Stem Cells with Different Combinations of Priming and Inducing Factors Toward Definitive Endoderm
Despite the enormous progress in studying definitive endoderm (DE) differentiation from human embryonic stem cells (hESCs), none of the reported protocols have produced a universal, cost-effective, and competent DE with the capability to further differentiate into endodermal derivatives. In this stu...
Gespeichert in:
Veröffentlicht in: | Stem cells and development 2013-05, Vol.22 (9), p.1419-1432 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1432 |
---|---|
container_issue | 9 |
container_start_page | 1419 |
container_title | Stem cells and development |
container_volume | 22 |
creator | Tahamtani, Yasser Azarnia, Mahnaz Farrokhi, Ali Sharifi-Zarchi, Ali Aghdami, Nasser Baharvand, Hossein |
description | Despite the enormous progress in studying definitive endoderm (DE) differentiation from human embryonic stem cells (hESCs), none of the reported protocols have produced a universal, cost-effective, and competent DE with the capability to further differentiate into endodermal derivatives. In this study, by using a 2-step differentiation strategy, we have treated hESCs for 1 day with “priming” small molecules (SM), [stauprimide, NSC-308848, rapamycin (Rapa), and/or CHIR] and for the next 3 days with “inducing” SM (LY294002, cymarin, IDE1, and/or IDE2) in conjunction with activin A. In the positive control group, we treated hESCs with Wnt3a (25 ng/mL) for 1 day and activin A (100 ng/mL; W/A100-A100) for the next 3 days. Gene expression analysis showed that treatment of hESCs with 100 nM Rapa and 50 ng/mL activin A (Rapa-A50) out of 25 combinations of factors gave rise to higher expressions of 2 DE-specific genes,
SOX17
and
FOXA2
. Similar results were obtained after treating 2 other hESC lines with this regimen. To investigate the competency of Rapa-A50-induced DE for further differentiation into endodermal derivatives, these cells and W/A100-A100-induced DE cells (positive control) were further differentiated into pancreatic progenitors (PP), then into pancreatic endocrine (PE) cells using 5 previously described differentiation protocols. Gene analysis of differentiated cells showed that the established protocols were insufficient to enable universal differentiation into PE, whereas Rapa-A50-induced DE cells were more competent for PP differentiation in a protocol-dependent manner. Additionally, Rapa-A50-induced DE had the capability to differentiate into hepatocyte-like cells (HLCs) as efficiently as W/A100-A100-induced DE. These data have indicated that hESCs primed with Rapa, and induced by a lower concentration of activin A, could lead to DE that had the capability to further differentiate into HLCs and PP cells, but not PE cells. Thus, current protocols for the differentiation of DE into PE still need additional study. |
doi_str_mv | 10.1089/scd.2012.0453 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1347259258</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1347259258</sourcerecordid><originalsourceid>FETCH-LOGICAL-c337t-4db70eebea78096746d1f7bffbd0c15c8a2ab1da70e823429ae61b120223ee883</originalsourceid><addsrcrecordid>eNqFkDtvFDEURi0EIiFQ0iKXNLP4NWtPiTYbEikSSCz1yI9rMFrbwfYkSsNvZ6wNtFS-vjr3k76D0FtKNpSo6UO1bsMIZRsiRv4MndNxlIMauXjeZyEHzpQ8Q69q_UkI2zIlXqIzxpmYOJnO0e9DAd0ipIazx9dL1AnvoymPOQWLvzaIeAfHY8UPof3Al8F7KB3e5WhC0i3kVPvllxJiSN-xTg7fJLfY_rnStuVS8SE_6OLwJfiQQgv3gPfJZQclvkYvvD5WePP0XqBvV_vD7nq4_fzpZvfxdrCcyzYIZyQBMKClItNWiq2jXhrvjSOWjlZppg11eoUU44JNGrbUUEYY4wBK8Qv0_pR7V_KvBWqbY6h2LaYT5KXOlAvJxomNHR1OqC251gJ-vlu76fI4UzJ35fOqfO7K56585d89RS8mgvtH_3W8AvwE9LVO6RjWIqX9J_YPBiKPhQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1347259258</pqid></control><display><type>article</type><title>Treatment of Human Embryonic Stem Cells with Different Combinations of Priming and Inducing Factors Toward Definitive Endoderm</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Tahamtani, Yasser ; Azarnia, Mahnaz ; Farrokhi, Ali ; Sharifi-Zarchi, Ali ; Aghdami, Nasser ; Baharvand, Hossein</creator><creatorcontrib>Tahamtani, Yasser ; Azarnia, Mahnaz ; Farrokhi, Ali ; Sharifi-Zarchi, Ali ; Aghdami, Nasser ; Baharvand, Hossein</creatorcontrib><description>Despite the enormous progress in studying definitive endoderm (DE) differentiation from human embryonic stem cells (hESCs), none of the reported protocols have produced a universal, cost-effective, and competent DE with the capability to further differentiate into endodermal derivatives. In this study, by using a 2-step differentiation strategy, we have treated hESCs for 1 day with “priming” small molecules (SM), [stauprimide, NSC-308848, rapamycin (Rapa), and/or CHIR] and for the next 3 days with “inducing” SM (LY294002, cymarin, IDE1, and/or IDE2) in conjunction with activin A. In the positive control group, we treated hESCs with Wnt3a (25 ng/mL) for 1 day and activin A (100 ng/mL; W/A100-A100) for the next 3 days. Gene expression analysis showed that treatment of hESCs with 100 nM Rapa and 50 ng/mL activin A (Rapa-A50) out of 25 combinations of factors gave rise to higher expressions of 2 DE-specific genes,
SOX17
and
FOXA2
. Similar results were obtained after treating 2 other hESC lines with this regimen. To investigate the competency of Rapa-A50-induced DE for further differentiation into endodermal derivatives, these cells and W/A100-A100-induced DE cells (positive control) were further differentiated into pancreatic progenitors (PP), then into pancreatic endocrine (PE) cells using 5 previously described differentiation protocols. Gene analysis of differentiated cells showed that the established protocols were insufficient to enable universal differentiation into PE, whereas Rapa-A50-induced DE cells were more competent for PP differentiation in a protocol-dependent manner. Additionally, Rapa-A50-induced DE had the capability to differentiate into hepatocyte-like cells (HLCs) as efficiently as W/A100-A100-induced DE. These data have indicated that hESCs primed with Rapa, and induced by a lower concentration of activin A, could lead to DE that had the capability to further differentiate into HLCs and PP cells, but not PE cells. Thus, current protocols for the differentiation of DE into PE still need additional study.</description><identifier>ISSN: 1547-3287</identifier><identifier>EISSN: 1557-8534</identifier><identifier>DOI: 10.1089/scd.2012.0453</identifier><identifier>PMID: 23249309</identifier><language>eng</language><publisher>United States: Mary Ann Liebert, Inc</publisher><subject>Activins - pharmacology ; Activins - physiology ; Antigens, Differentiation - genetics ; Antigens, Differentiation - metabolism ; Cell Differentiation - drug effects ; Cells, Cultured ; Embryonic Stem Cells - drug effects ; Embryonic Stem Cells - physiology ; Endoderm - cytology ; Endoderm - metabolism ; Gene Expression ; Glycogen - biosynthesis ; Hepatocyte Nuclear Factor 3-beta - genetics ; Hepatocyte Nuclear Factor 3-beta - metabolism ; Humans ; Liver - cytology ; Liver - metabolism ; Original Research Reports ; Pancreas - cytology ; Sirolimus - pharmacology ; SOXF Transcription Factors - genetics ; SOXF Transcription Factors - metabolism ; TOR Serine-Threonine Kinases - antagonists & inhibitors</subject><ispartof>Stem cells and development, 2013-05, Vol.22 (9), p.1419-1432</ispartof><rights>2013, Mary Ann Liebert, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c337t-4db70eebea78096746d1f7bffbd0c15c8a2ab1da70e823429ae61b120223ee883</citedby><cites>FETCH-LOGICAL-c337t-4db70eebea78096746d1f7bffbd0c15c8a2ab1da70e823429ae61b120223ee883</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23249309$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tahamtani, Yasser</creatorcontrib><creatorcontrib>Azarnia, Mahnaz</creatorcontrib><creatorcontrib>Farrokhi, Ali</creatorcontrib><creatorcontrib>Sharifi-Zarchi, Ali</creatorcontrib><creatorcontrib>Aghdami, Nasser</creatorcontrib><creatorcontrib>Baharvand, Hossein</creatorcontrib><title>Treatment of Human Embryonic Stem Cells with Different Combinations of Priming and Inducing Factors Toward Definitive Endoderm</title><title>Stem cells and development</title><addtitle>Stem Cells Dev</addtitle><description>Despite the enormous progress in studying definitive endoderm (DE) differentiation from human embryonic stem cells (hESCs), none of the reported protocols have produced a universal, cost-effective, and competent DE with the capability to further differentiate into endodermal derivatives. In this study, by using a 2-step differentiation strategy, we have treated hESCs for 1 day with “priming” small molecules (SM), [stauprimide, NSC-308848, rapamycin (Rapa), and/or CHIR] and for the next 3 days with “inducing” SM (LY294002, cymarin, IDE1, and/or IDE2) in conjunction with activin A. In the positive control group, we treated hESCs with Wnt3a (25 ng/mL) for 1 day and activin A (100 ng/mL; W/A100-A100) for the next 3 days. Gene expression analysis showed that treatment of hESCs with 100 nM Rapa and 50 ng/mL activin A (Rapa-A50) out of 25 combinations of factors gave rise to higher expressions of 2 DE-specific genes,
SOX17
and
FOXA2
. Similar results were obtained after treating 2 other hESC lines with this regimen. To investigate the competency of Rapa-A50-induced DE for further differentiation into endodermal derivatives, these cells and W/A100-A100-induced DE cells (positive control) were further differentiated into pancreatic progenitors (PP), then into pancreatic endocrine (PE) cells using 5 previously described differentiation protocols. Gene analysis of differentiated cells showed that the established protocols were insufficient to enable universal differentiation into PE, whereas Rapa-A50-induced DE cells were more competent for PP differentiation in a protocol-dependent manner. Additionally, Rapa-A50-induced DE had the capability to differentiate into hepatocyte-like cells (HLCs) as efficiently as W/A100-A100-induced DE. These data have indicated that hESCs primed with Rapa, and induced by a lower concentration of activin A, could lead to DE that had the capability to further differentiate into HLCs and PP cells, but not PE cells. Thus, current protocols for the differentiation of DE into PE still need additional study.</description><subject>Activins - pharmacology</subject><subject>Activins - physiology</subject><subject>Antigens, Differentiation - genetics</subject><subject>Antigens, Differentiation - metabolism</subject><subject>Cell Differentiation - drug effects</subject><subject>Cells, Cultured</subject><subject>Embryonic Stem Cells - drug effects</subject><subject>Embryonic Stem Cells - physiology</subject><subject>Endoderm - cytology</subject><subject>Endoderm - metabolism</subject><subject>Gene Expression</subject><subject>Glycogen - biosynthesis</subject><subject>Hepatocyte Nuclear Factor 3-beta - genetics</subject><subject>Hepatocyte Nuclear Factor 3-beta - metabolism</subject><subject>Humans</subject><subject>Liver - cytology</subject><subject>Liver - metabolism</subject><subject>Original Research Reports</subject><subject>Pancreas - cytology</subject><subject>Sirolimus - pharmacology</subject><subject>SOXF Transcription Factors - genetics</subject><subject>SOXF Transcription Factors - metabolism</subject><subject>TOR Serine-Threonine Kinases - antagonists & inhibitors</subject><issn>1547-3287</issn><issn>1557-8534</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkDtvFDEURi0EIiFQ0iKXNLP4NWtPiTYbEikSSCz1yI9rMFrbwfYkSsNvZ6wNtFS-vjr3k76D0FtKNpSo6UO1bsMIZRsiRv4MndNxlIMauXjeZyEHzpQ8Q69q_UkI2zIlXqIzxpmYOJnO0e9DAd0ipIazx9dL1AnvoymPOQWLvzaIeAfHY8UPof3Al8F7KB3e5WhC0i3kVPvllxJiSN-xTg7fJLfY_rnStuVS8SE_6OLwJfiQQgv3gPfJZQclvkYvvD5WePP0XqBvV_vD7nq4_fzpZvfxdrCcyzYIZyQBMKClItNWiq2jXhrvjSOWjlZppg11eoUU44JNGrbUUEYY4wBK8Qv0_pR7V_KvBWqbY6h2LaYT5KXOlAvJxomNHR1OqC251gJ-vlu76fI4UzJ35fOqfO7K56585d89RS8mgvtH_3W8AvwE9LVO6RjWIqX9J_YPBiKPhQ</recordid><startdate>20130501</startdate><enddate>20130501</enddate><creator>Tahamtani, Yasser</creator><creator>Azarnia, Mahnaz</creator><creator>Farrokhi, Ali</creator><creator>Sharifi-Zarchi, Ali</creator><creator>Aghdami, Nasser</creator><creator>Baharvand, Hossein</creator><general>Mary Ann Liebert, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20130501</creationdate><title>Treatment of Human Embryonic Stem Cells with Different Combinations of Priming and Inducing Factors Toward Definitive Endoderm</title><author>Tahamtani, Yasser ; Azarnia, Mahnaz ; Farrokhi, Ali ; Sharifi-Zarchi, Ali ; Aghdami, Nasser ; Baharvand, Hossein</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c337t-4db70eebea78096746d1f7bffbd0c15c8a2ab1da70e823429ae61b120223ee883</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Activins - pharmacology</topic><topic>Activins - physiology</topic><topic>Antigens, Differentiation - genetics</topic><topic>Antigens, Differentiation - metabolism</topic><topic>Cell Differentiation - drug effects</topic><topic>Cells, Cultured</topic><topic>Embryonic Stem Cells - drug effects</topic><topic>Embryonic Stem Cells - physiology</topic><topic>Endoderm - cytology</topic><topic>Endoderm - metabolism</topic><topic>Gene Expression</topic><topic>Glycogen - biosynthesis</topic><topic>Hepatocyte Nuclear Factor 3-beta - genetics</topic><topic>Hepatocyte Nuclear Factor 3-beta - metabolism</topic><topic>Humans</topic><topic>Liver - cytology</topic><topic>Liver - metabolism</topic><topic>Original Research Reports</topic><topic>Pancreas - cytology</topic><topic>Sirolimus - pharmacology</topic><topic>SOXF Transcription Factors - genetics</topic><topic>SOXF Transcription Factors - metabolism</topic><topic>TOR Serine-Threonine Kinases - antagonists & inhibitors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tahamtani, Yasser</creatorcontrib><creatorcontrib>Azarnia, Mahnaz</creatorcontrib><creatorcontrib>Farrokhi, Ali</creatorcontrib><creatorcontrib>Sharifi-Zarchi, Ali</creatorcontrib><creatorcontrib>Aghdami, Nasser</creatorcontrib><creatorcontrib>Baharvand, Hossein</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Stem cells and development</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tahamtani, Yasser</au><au>Azarnia, Mahnaz</au><au>Farrokhi, Ali</au><au>Sharifi-Zarchi, Ali</au><au>Aghdami, Nasser</au><au>Baharvand, Hossein</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of Human Embryonic Stem Cells with Different Combinations of Priming and Inducing Factors Toward Definitive Endoderm</atitle><jtitle>Stem cells and development</jtitle><addtitle>Stem Cells Dev</addtitle><date>2013-05-01</date><risdate>2013</risdate><volume>22</volume><issue>9</issue><spage>1419</spage><epage>1432</epage><pages>1419-1432</pages><issn>1547-3287</issn><eissn>1557-8534</eissn><abstract>Despite the enormous progress in studying definitive endoderm (DE) differentiation from human embryonic stem cells (hESCs), none of the reported protocols have produced a universal, cost-effective, and competent DE with the capability to further differentiate into endodermal derivatives. In this study, by using a 2-step differentiation strategy, we have treated hESCs for 1 day with “priming” small molecules (SM), [stauprimide, NSC-308848, rapamycin (Rapa), and/or CHIR] and for the next 3 days with “inducing” SM (LY294002, cymarin, IDE1, and/or IDE2) in conjunction with activin A. In the positive control group, we treated hESCs with Wnt3a (25 ng/mL) for 1 day and activin A (100 ng/mL; W/A100-A100) for the next 3 days. Gene expression analysis showed that treatment of hESCs with 100 nM Rapa and 50 ng/mL activin A (Rapa-A50) out of 25 combinations of factors gave rise to higher expressions of 2 DE-specific genes,
SOX17
and
FOXA2
. Similar results were obtained after treating 2 other hESC lines with this regimen. To investigate the competency of Rapa-A50-induced DE for further differentiation into endodermal derivatives, these cells and W/A100-A100-induced DE cells (positive control) were further differentiated into pancreatic progenitors (PP), then into pancreatic endocrine (PE) cells using 5 previously described differentiation protocols. Gene analysis of differentiated cells showed that the established protocols were insufficient to enable universal differentiation into PE, whereas Rapa-A50-induced DE cells were more competent for PP differentiation in a protocol-dependent manner. Additionally, Rapa-A50-induced DE had the capability to differentiate into hepatocyte-like cells (HLCs) as efficiently as W/A100-A100-induced DE. These data have indicated that hESCs primed with Rapa, and induced by a lower concentration of activin A, could lead to DE that had the capability to further differentiate into HLCs and PP cells, but not PE cells. Thus, current protocols for the differentiation of DE into PE still need additional study.</abstract><cop>United States</cop><pub>Mary Ann Liebert, Inc</pub><pmid>23249309</pmid><doi>10.1089/scd.2012.0453</doi><tpages>14</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1547-3287 |
ispartof | Stem cells and development, 2013-05, Vol.22 (9), p.1419-1432 |
issn | 1547-3287 1557-8534 |
language | eng |
recordid | cdi_proquest_miscellaneous_1347259258 |
source | MEDLINE; Alma/SFX Local Collection |
subjects | Activins - pharmacology Activins - physiology Antigens, Differentiation - genetics Antigens, Differentiation - metabolism Cell Differentiation - drug effects Cells, Cultured Embryonic Stem Cells - drug effects Embryonic Stem Cells - physiology Endoderm - cytology Endoderm - metabolism Gene Expression Glycogen - biosynthesis Hepatocyte Nuclear Factor 3-beta - genetics Hepatocyte Nuclear Factor 3-beta - metabolism Humans Liver - cytology Liver - metabolism Original Research Reports Pancreas - cytology Sirolimus - pharmacology SOXF Transcription Factors - genetics SOXF Transcription Factors - metabolism TOR Serine-Threonine Kinases - antagonists & inhibitors |
title | Treatment of Human Embryonic Stem Cells with Different Combinations of Priming and Inducing Factors Toward Definitive Endoderm |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T09%3A52%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20Human%20Embryonic%20Stem%20Cells%20with%20Different%20Combinations%20of%20Priming%20and%20Inducing%20Factors%20Toward%20Definitive%20Endoderm&rft.jtitle=Stem%20cells%20and%20development&rft.au=Tahamtani,%20Yasser&rft.date=2013-05-01&rft.volume=22&rft.issue=9&rft.spage=1419&rft.epage=1432&rft.pages=1419-1432&rft.issn=1547-3287&rft.eissn=1557-8534&rft_id=info:doi/10.1089/scd.2012.0453&rft_dat=%3Cproquest_cross%3E1347259258%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1347259258&rft_id=info:pmid/23249309&rfr_iscdi=true |